Deflazacort
A synthetic oxazoline glucocorticoid derived from prednisolone, used as an anti-inflammatory and immunosuppressant and specifically approved for Duchenne muscular dystrophy in the United States. It is considered to have a better safety profile regarding bone loss and weight gain compared to equivalent doses of prednisone.
Berat Molekul
441,5000 g/mol
LogP
2,00
TPSA
102,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Suppresses the immune system by inhibiting T-cell activation, lymphocyte proliferation, or cytokine production. This prevents immune-mediated tissue damage and graft rejection.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Suppresses the immune system by inhibiting T-cell activation, lymphocyte proliferation, or cytokine production. This prevents immune-mediated tissue damage and graft rejection.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C
InChI
InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
Molecular Formula
C25H31NO6
HBD / HBA
1 / 7
Ikatan yang Dapat Dirotasi
4
Atom Berat
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A synthetic oxazoline glucocorticoid derived from prednisolone, used as an anti-inflammatory and immunosuppressant and specifically approved for Duchenne muscular dystrophy in the United States. It is considered to have a better safety profile regarding bone loss and weight gain compared to equivalent doses of prednisone.
Suppresses the immune system by inhibiting T-cell activation, lymphocyte proliferation, or cytokine production. This prevents immune-mediated tissue damage and graft rejection.
Yes, Deflazacort is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201891. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 189821. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="deflazacort"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/deflazacort/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/deflazacort/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/deflazacort/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="deflazacort"></drugfyi-drug>